WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has been named to the 2014 Best Adoption-Friendly Workplaces List by the Dave Thomas Foundation for Adoption. For the second consecutive year, and third time in four years, PPD made the list honoring the top 100 U.S. companies that support families seeking to adopt.
The annual list helps increase awareness about foster care adoption, while celebrating businesses that support adoptive families. Rankings are determined by an analysis of a company’s resources available for employees who adopt children. PPD’s benefits include paid leave and reimbursement toward expenses incurred during the adoption process.
“Employees are the foundation of PPD’s success,” said Ed Murray, executive vice president and chief human resources officer for PPD. “The company believes strongly in supporting work-life balance for employees and their families. Assisting families who seek adoption is one way PPD helps make a difference in the lives of employees and their children. We are honored to earn this prestigious recognition.”
Adoption assistance is part of PPD’s comprehensive benefits and resources that support its commitment to employee health and wellness. The company continually evaluates and implements innovative programs that meet the work-life balance needs of employees.
“We are incredibly excited and grateful to see a growing number of employers across the country provide adoption benefits for employees,” said Rita Soronen, president and chief executive officer of the Dave Thomas Foundation for Adoption. “Adoption, and in particular adoption from foster care, is an important and increasingly common path to parenthood; we commend all of the employers across the country who recognize the importance of providing benefits to employees looking to expand their families through adoption.”
Created by Wendy’s® founder Dave Thomas, who was adopted, the foundation is a national nonprofit public charity dedicated exclusively to finding permanent homes for the more than 134,000 children waiting in North America’s foster care systems.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s employee benefits, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; the ability to control SG&A spending; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; rapid technological advances that make our services or capabilities less competitive; risks associated with acquisitions and investments; compliance with drug development regulations; changes in the regulation of the drug development process; and consolidation in the pharmaceutical and biotechnology industries;. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.